Investor's Business Daily on MSN5d
Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't WorriedDexcom stock plunged to a four-month low Monday after the FDA issued a warning letter tied to inspections of two facilities ...
The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and ...
Zacks Investment Research on MSN1d
DexCom CGM Sensor Sales to Continue Despite FDA Warning LetterDexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...
DexCom Inc. closed 51.77% below its 52-week high of $142.00, which the company achieved on March 26th.
The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...
Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...
Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...
DexCom Inc. closed 50.22% short of its 52-week high of $142.00, which the company achieved on March 26th.
Dexcom announced today that it received a warning letter from the FDA following inspections of two company facilities.
(NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025. Ms. Galá is an accomplished executive with ...
PNC Financial Services Group Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% in the fourth ...
DexCom (DXCM) does not expect a material impact from the FDA’s warning letter to its manufacturing capacity or its fiscal year 2025 guidance ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback